Doctours is a curated medical tourism marketplace that guides Americans through international hair transplants, its beachhead into a broader cross-border care platform. The wedge is trust plus affordability: transparent all-in pricing, vetted clinics, and installment financing no incumbent offers, matched to the roughly 200,000 Americans who pursue hair transplants each year.
Validation signals as of the 2025-10-03 September investor update: cumulative revenue reached $27,202 on $267,917 lifetime GMV, with the highest paid-booking month since launch (per note recEHIhYKh29xE5vt). LAUNCH (Jason Calacanis) led the round, unusual for the accelerator, with Draper Associates and Jesse Draper's Halogen also participating. SH committed $300K via StoryHouse Fund II into the $8M cap Pre-Seed SAFE, part of a roughly $1.6M round, closing 2025-10-21. A later extension noted in Airtable added HMC Inc and Halogen at a $12M cap.
Hair transplants are a multi-billion-dollar, double-digit-growth beachhead: web sources put the 2025 global market near $6.4B growing about 8.8% a year Web, while founder-supplied research (Medihair) cites roughly $9.5B and about 14% growth. Doctours targets the roughly 200,000 Americans undergoing hair transplants annually as its entry into the broader $150B medical tourism industry, with IVF flagged as the intended second vertical.
| Company | Focus | Funding / Stage | Note |
|---|---|---|---|
| Doctours | US-to-international medical tourism marketplace; hair transplant beachhead | Pre-Seed, $1.6M at $8M cap | 100+ vetted clinics, installment financing, TikTok creator CAC |
| Heva | Turkey hair transplant / medical tourism | ~$3M raised, launched Mar 2025 Internal | Direct startup competitor (founder-identified) |
| Essos | Medical tourism platform, hair transplant + facial | ~$8M raised, still pre-product Internal | Better funded but unlaunched |
| Bookimed | Global medical tourism marketplace | Founded 2014, incumbent Web | 1M+ patients, broad procedure coverage |
| Qunomedical | Digital-first medical tourism platform | Berlin, ~€10M Series A (2022) Web | Review-rich incumbent, IMTJ awards |
Moat: Doctours' edge is two-sided marketplace liquidity as first mover on the US-to-clinic axis, proprietary creator-led TikTok acquisition at sub-$1 CPM, installment financing no rival offers, and a planned supply lock-up buying discounted clinic capacity (partners run about 50% vacancy) before competitors can.
Most recent verified figures are from the September 2025 investor update; no confirmed metrics for the roughly nine months since. Airtable lists estimated LTM revenue of about $50K.
Likely acquirers include larger medical tourism platforms such as Bookimed, Qunomedical, or PlacidWay, or consumer-health players moving into hair and elective care (for example Hims & Hers). Medical tourism M&A is thin, so continued marketplace scaling and later-stage financing is a more probable path than a near-term exit. The most relevant comparable financing is Qunomedical's roughly €10M Series A (2022) Web.
September investor update from Girum Tihtina, CEO. Doctours is a medical tourism marketplace starting with hair transplants. The team announced acquiring the Doctours.com domain as a milestone toward building a household brand.
September figures: total revenue $27,202, September revenue $6,250, total GMV $267,917, September GMV $79,706, team size 7. September delivered the highest number of paid bookings since launch, credited to optimized customer-success processes and ramped top-of-funnel growth.
The CEO framed hair transplants as an elective, high-margin beachhead validating that Americans will travel for non-emergency care, with IVF as the next market and a mission to make healthcare affordable for lower-income Americans. Marketing: an early-September test sponsoring hair-transplant procedures for content creators became the most successful campaign to date, driving CPM below $0.50 and generating the most qualified leads since launch; 80% of September conversions came from it, and the program is being scaled.
Source: Meeting Notes recEHIhYKh29xE5vtThird call with the Doctours team. Summary: Matthew and Josh both mid-positive. Attractive Pre-Seed opportunity in an attractive, large market, but still early (roughly $4K per booking, tens of bookings a month) with meaningful execution risk and a low-signal investor syndicate.
Metrics: August funnel of 892 booking requests, 80 completed calls, 16 paid bookings; September reached 26 paid bookings (versus 42 projected) and $79,706 GMV. Average transaction value about $4K with a 10-20% commission, and the first booking without a sales call happened in September. Major drop-off: only about 10% of booking requests convert to calls.
Business model: 10% commission initially, scaling to 20-30% after 10 patients per month per clinic; package covers everything except flights. Matt flagged the offering as significantly underpriced. Key challenges: sales dependency on new hire Rick, trust objections from customers, and website conversion (810 of 892 requests drop before scheduling). Fixes in progress: full website and user-journey redesign, an AI hairline-visualization tool, better clinic matching, and pre-qualification. Fundraising: LAUNCH syndicate plus fund check, deadline extended to October 6; Draper Associates and Halogen interested; $8M SAFE cap; likely mid-to-late October close. StoryHouse to provide an answer the following week.
Source: Meeting Notes recLYT34iLyHL1jj4Call with Kelly Schricker, Managing Director at LAUNCH, who is leading the investment into Doctours (roughly $800K to StoryHouse's knowledge). LAUNCH is an angel-to-growth platform with 10,000+ syndicate members and multiple programs (Founder University, a 12-week accelerator, and a syndicate with $500K minimum checks). Doctours went through the accelerator.
LAUNCH's structure for Doctours: initial $125K for 7% (accelerator check), a $165K fund follow-on at an $8M valuation, and a $500K syndicate target at $8M with their LP group, all new capital via SAFE at $8M pre-money. It is unusual for LAUNCH to lead, but high investor interest drove an early term sheet in August; they were awaiting financials before launching the syndicate. Board observer is standard, with a seat if ownership exceeds 5%. Investment thesis: marketplace business model (a LAUNCH favorite), a serial founding team with prior collaboration, and an outlier, contrarian opportunity in a growing market. Diligence was led by Kelly; Jason Calacanis led the effort to sign the team.
Source: Meeting Notes rectIfEYAv8cijPSJ2025-10-01 — Kelly Schricker (LAUNCH MD): Reference call regarding founder Girum Tihtina and the round LAUNCH is leading. Kelly confirmed LAUNCH's staged structure ($125K accelerator for 7%, $165K fund follow-on, $500K syndicate target, all at an $8M SAFE cap) and noted it is unusual for LAUNCH to lead out of its accelerator, driven by strong demo-day interest and an early August term sheet. Board observer is standard, with a seat above 5% ownership (Meeting Notes rectIfEYAv8cijPSJ).